AB 1944 Summary

• Establishes the Right to Try Individualized Investigational Treatments Act, permitting manufacturers operating in eligible facilities to make individualized investigational treatments available to eligible patients with life-threatening or severely debilitating illnesses.

• Defines eligible patients as those who have exhausted FDA-approved treatment options, received physician recommendation based on genetic or cellular analysis, and provided written informed consent with specific disclosures about risks and outcomes.

• Prohibits state regulatory boards from revoking, suspending, or taking action against a health care provider's license solely based on recommending or providing access to individualized investigational treatments.

• Allows health benefit plans to voluntarily cover individualized investigational treatments but does not require coverage; patients may be charged for manufacturing costs or receive treatment at no cost.

• Protects manufacturers and health care providers from private lawsuits for harm resulting from individualized investigational treatments when acting in good faith compliance with the law.